Serum Mimecan Associated with Arterial Stiffness in Hypertensive Patients
By LabMedica International staff writers Posted on 18 Aug 2015 |
Mimecan plays an important role in endothelial and vascular smooth muscle cell integrity and may be involved the pathology of arterial stiffness; however, the role of mimecan in arterial stiffness in patients with hypertension is not well defined.
Arterial stiffness is recognized to be an independent risk factor for cardiovascular (CV) morbidity and mortality and it is the root cause of a range of CV complications, including myocardial infarction (MI), left ventricular hypertrophy, stroke, renal failure, dementia, and death, as well as a hallmark of the aging process.
Scientists at the Second Affiliated Hospital of Soochow University (Suzhou, China), enrolled a total of 116 hypertension patients and 54 healthy controls to investigated the association between serum mimecan concentration and arterial stiffness, as measured by brachial‐ankle pulse wave velocity (baPWV), in patients with hypertension. Hypertensive patients were divided into two groups: 83 with arterial stiffness defined by a baPWV of equal to or greater than 1,400 cm/s; and the 3, in the without arterial stiffness group, whose baPWV was less than 1,400 cm/s.
Routine biochemical measurements were performed on each blood sample using an AU5400 automated chemistry analyzer (Beckman Coulter; Fullerton, CA, USA). Circulating mimecan concentrations were determined using the human mimecan enzyme-linked immunosorbent assay (ELISA) kit (antibodies‐online Inc., Atlanta, GA, USA) that has a detection range of this kit is 20 ng/mL to 0.313 ng/mL and sensitivity is 0.133 ng/mL. Circulating endothelin 1 (ET‐1) concentrations were determined using the human ET‐1 ELISA kit (R&D Systems; Minneapolis, MN, USA) that has detection range of 0.34 to 250 pg/mL and its sensitivity is 0.102 pg/mL.
Hypertensive patients had higher baPWV, mimecan, and endothelin 1 than healthy controls. Mean mimecan levels were 13.7ng/mL in the hypertensive group compared to 8.32 ng/mL in the healthy controls. The arterial stiffness group had higher mimecan and endothelin 1 (ET‐1) and lower ankle‐brachial pressure index (ABI) than those without stiffness. In hypertensive patients, mimecan was inversely correlated with ABI and positively correlated with baPWV, ET‐1, and total cholesterol. Diastolic blood pressure, mimecan, ET‐1, and creatinine were independent predictors of arterial stiffness in hypertensive patients.
The authors conclude that mimecan levels are higher in hypertensive patients than in healthy controls and increased plasma mimecan levels are independently associated with increased arterial stiffness as assessed by baPWV. The study was published on July 23, 2015, in the Journal of the American Heart Association (JAHA).
Related Links:
Second Affiliated Hospital of Soochow University
Beckman Coulter
antibodies‐online Inc.
Arterial stiffness is recognized to be an independent risk factor for cardiovascular (CV) morbidity and mortality and it is the root cause of a range of CV complications, including myocardial infarction (MI), left ventricular hypertrophy, stroke, renal failure, dementia, and death, as well as a hallmark of the aging process.
Scientists at the Second Affiliated Hospital of Soochow University (Suzhou, China), enrolled a total of 116 hypertension patients and 54 healthy controls to investigated the association between serum mimecan concentration and arterial stiffness, as measured by brachial‐ankle pulse wave velocity (baPWV), in patients with hypertension. Hypertensive patients were divided into two groups: 83 with arterial stiffness defined by a baPWV of equal to or greater than 1,400 cm/s; and the 3, in the without arterial stiffness group, whose baPWV was less than 1,400 cm/s.
Routine biochemical measurements were performed on each blood sample using an AU5400 automated chemistry analyzer (Beckman Coulter; Fullerton, CA, USA). Circulating mimecan concentrations were determined using the human mimecan enzyme-linked immunosorbent assay (ELISA) kit (antibodies‐online Inc., Atlanta, GA, USA) that has a detection range of this kit is 20 ng/mL to 0.313 ng/mL and sensitivity is 0.133 ng/mL. Circulating endothelin 1 (ET‐1) concentrations were determined using the human ET‐1 ELISA kit (R&D Systems; Minneapolis, MN, USA) that has detection range of 0.34 to 250 pg/mL and its sensitivity is 0.102 pg/mL.
Hypertensive patients had higher baPWV, mimecan, and endothelin 1 than healthy controls. Mean mimecan levels were 13.7ng/mL in the hypertensive group compared to 8.32 ng/mL in the healthy controls. The arterial stiffness group had higher mimecan and endothelin 1 (ET‐1) and lower ankle‐brachial pressure index (ABI) than those without stiffness. In hypertensive patients, mimecan was inversely correlated with ABI and positively correlated with baPWV, ET‐1, and total cholesterol. Diastolic blood pressure, mimecan, ET‐1, and creatinine were independent predictors of arterial stiffness in hypertensive patients.
The authors conclude that mimecan levels are higher in hypertensive patients than in healthy controls and increased plasma mimecan levels are independently associated with increased arterial stiffness as assessed by baPWV. The study was published on July 23, 2015, in the Journal of the American Heart Association (JAHA).
Related Links:
Second Affiliated Hospital of Soochow University
Beckman Coulter
antibodies‐online Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines